Research Progress on EGFR-TKI Targeted Therapy for Non-Small Cell Lung Cancer
Targeted therapy represented by epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs)has significantly improved the prognosis of patients with non-small cell lung cancer(NSCLC).The efficacy of EGFR-TKIs(including EGFR-TKIs monotherapy and combined with chemotherapy,anti-angiogenesis therapy and immunotherapy)in neoadjuvant therapy,adjuvant therapy and first-line treatment for advanced-stage patients has been extensively explored.However,resis-tance to EGFR-TKIs in targeted therapy has become a challenge leading to the difficulty in post-resis-tance treatment.This paper reviews the clinical application,resistance mechanisms and anti-resis-tance treatments of EGFR-TKIs.
NETL
NSTL
万方数据
